Health Tech Daily Brief - October 24, 2026

Here is everything that moved in healthcare technology over the past day - 172 stories curated by the HTC news desk across AI, telehealth, wearables, health IT, policy, funding, and digital therapeutics.

AI in Healthcare

MedTech Innovation Drives Transformation Across India’s Healthcare Sector

The Indian Practitioner2026-10-24

The future of medicine is already here. These are the breakthroughs shaping what comes next

Fast Company Middle East2026-10-24

UK pledges to spend £600m to defend against AI health and security threats

Sky News2026-10-24

Telehealth & Virtual Care

Calls for Change in the Regulation of Telehealth Medicine

The Regulatory Review2026-10-24

Mass General Brigham layoffs reportedly underway, along with Home Hospital program cuts

CBS News2026-10-23

Telemedicine Firms Push Back on Korea's 7-Day Prescription Cap

Seoul Economic Daily2026-10-23

Wearables & Remote Monitoring

Alloop Trio health wearable swaps from band to ring for sleep

Techlicious2026-10-24

Don’t Turn Back the Clock on Diabetes Care

The Well News2026-10-23

Wirelessly Powered Electronic Implant, ECHO, Enables Drug-Free Management of 'Diabesity'

Genetic Engineering and Biotechnology News2026-10-23

Health IT & Security

Where Are the Biggest Opportunities in Women’s Cardiovascular Health?

MedTech Conference panelists cited inflammation research, listening to women, clinical trial representation and investment as priorities for women’s cardiovascular health. The post Where Are the Biggest Opportunities in Women’s Cardiovascular Health? appeared first on MedCity News.

medcitynews.com2026-10-23

Russian cybercrime suspect linked to deadly London hospital attack

www.systemtek.co.uk2026-10-23

Gilead to Pay $1.3B for Oral Peptide That Could Rival J&J’s New Immunology Pill

Gilead Sciences is getting global rights to an experimental PepStar Therapeutics oral peptide designed to inhibit the IL-23 receptor to treat inflammatory bowel disease. It could compete against Johnson & Johnson’s Icotyde, an oral peptide that blocks the same target and is also in development for IBD. The post Gilead to Pay $1.3B for Oral Peptide That Could Rival J&J’s New Immunology Pill …

medcitynews.com2026-10-23